Themis Medicare Ltd. Share Price & Stock Analysis

Themis Medicare Ltd. (BSE: 530199) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹941 Cr, it ranks #1,624 by market cap among the 6,197 Indian listed companies on FinBizNet, and #48 of 86 in Medicinal Chemicals and Botanical Products. At ₹102.00 (as of 16 Nov 2026), the share price is 27.5% below its 52-week high of ₹140.60 and 57.0% above its 52-week low of ₹64.95. The share price is down 13.1% over one year and down 2.9% over three months.

Key Metrics

Current Price₹102.00
Market Cap₹941 Cr
BSE Code530199
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio854.8
Return on Equity0.29%
Return on Assets-1.05%
52-Week Range₹64.95 – ₹140.60
1-Year Price Change-13.1%
3-Month Price Change-2.9%
Beta (1Y)0.4
Dividend Yield0.49%
HeadquartersMumbai, Maharashtra
Websitewww.themismedicare.com

Latest Quarterly Results — Q2 FY27

Revenue₹90 Cr
Net Profit₹7 Cr
Net Margin7.9%
EPS (Basic)₹0.77
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Themis Medicare Ltd. Quarterly Revenue and Profit Trend

Themis Medicare Ltd. reported revenue of ₹90 Cr in Q2 FY27, up 15.1% from ₹78 Cr in Q2 FY26 and up 3.2% from ₹87 Cr in Q1 FY27. It posted a net profit of ₹7 Cr for the quarter, against a net loss of ₹4 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹72 Cr (Q4 FY25) to ₹98 Cr (Q1 FY26). The company reported a net loss in 3 of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹90 Cr₹7 Cr7.9%
Q1 FY27₹87 Cr₹25 Cr28.3%
Q4 FY26₹77 Cr₹9 Cr11.6%
Q3 FY26₹90 Cr₹10 Cr11.2%
Q2 FY26₹78 Cr−₹4 Cr−4.6%
Q1 FY26₹98 Cr−₹14 Cr−14.6%
Q4 FY25₹72 Cr−₹10 Cr−13.5%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 67.11% of Themis Medicare Ltd.'s shares as of Sept 2026, against 67.15% in Sept 2025 (−0.04 percentage points). Delivery averaged 46.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Themis Medicare Ltd.

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopr

Products and Services

1. Pharmaceuticals-This segment manufactures and sells pharmaceutical products. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, such as anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management.

Business Segments

1. Pharmaceuticals-100%

Themis Medicare Ltd. vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Themis Medicare Ltd.₹941 Cr854.80.29%₹90 Cr-13.1%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Themis Medicare Ltd.?

Themis Medicare Ltd. is trading at ₹102.00, with a market capitalisation of ₹941 Cr.

Which sector does Themis Medicare Ltd. belong to?

Themis Medicare Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Themis Medicare Ltd.?

Themis Medicare Ltd. has a P/E of 854.8 and a return on equity of 0.29%.

What is the stock symbol of Themis Medicare Ltd.?

Themis Medicare Ltd. is listed on the BSE under the scrip code 530199.

How has Themis Medicare Ltd.'s share price moved over the past year?

Themis Medicare Ltd.'s share price is down 13.1% over one year and down 2.9% over three months. Its 52-week range is ₹64.95 to ₹140.60.

What were Themis Medicare Ltd.'s latest quarterly results?

In Q2 FY27, Themis Medicare Ltd. reported revenue of ₹90 Cr and net profit of ₹7 Cr, with basic EPS of ₹0.77 (consolidated, parsed from the company's exchange filing).

How have Themis Medicare Ltd.'s revenue and profit changed over the past year?

Themis Medicare Ltd. reported revenue of ₹90 Cr in Q2 FY27, up 15.1% from ₹78 Cr in Q2 FY26 and up 3.2% from ₹87 Cr in Q1 FY27.

What is the promoter holding in Themis Medicare Ltd.?

Promoters held 67.11% of Themis Medicare Ltd.'s shares as of Sept 2026, against 67.15% in Sept 2025 (−0.04 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.